News habe ich im Internet noch keine gefunden,

An der Heimatbörse heute nichts Auffäliges,


Es tut dem Wert nur gut, wenn endlich mal Volumen reinkommt.

Bis jezt über 150 `TSD, das ist das 15 Fache, des früheren Volumens.

 

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN Time & Sales most recent  next page Rec. Time Action Price Volume 1:18:30 PM Bid 4.15 10000 1:11:50 PM Bid 4.15 10100 1:11:48 PM Bid 4.15 10000 1:11:48 PM Bid 4.16 100 1:11:48 PM Ask 4.2 1000 1:11:26 PM Bid 4.16 200 1:11:26 PM Ask 4.24 100 1:11:16 PM Ask 4.25 1000 1:11:16 PM Bid 4.16 100 1:09:50 PM Bid 4.16 200 1:09:14 PM Bid 4.16 100 1:09:14 PM Bid 4.15 10000 1:09:14 PM Bid 4.15 10100 1:09:14 PM Bid 4.17 100 1:09:14 PM Bid 4.15 10000 1:09:12 PM Ask 4.24 100 1:09:12 PM Bid 4.16 100 1:09:12 PM Bid 4.15 10000 1:09:00 PM Bid 4.16 100 1:09:00 PM Ask 4.25 1000 1:08:34 PM Bid 4.16 200 1:06:56 PM Ask 4.24 100 1:06:44 PM Ask 4.25 1000 1:04:46 PM Ask 4.24 100 1:04:46 PM Trade 4.2 4000 1:04:46 PM Trade 4.2 100 1:04:38 PM Bid 4.16 100 1:03:14 PM Ask 4.25 1000 1:02:08 PM Trade 4.25 15000 1:01:42 PM Bid 4.2 100 1:01:42 PM Bid 4.15 10000 1:01:42 PM Bid 4.16 100 12:57:40 PM Ask 4.26 200 12:57:36 PM Ask 4.28 100 12:56:28 PM Ask 4.26 200 12:56:20 PM Ask 4.27 100 12:56:20 PM Ask 4.27 300 12:56:04 PM Trade 4.27 2000 12:55:52 PM Ask 4.27 500 12:53:48 PM Ask 4.27 300 12:51:18 PM Trade 4.25 4900 12:51:18 PM Trade 4.25 100 12:49:42 PM Ask 4.27 100 12:49:04 PM Trade 4.25 900 12:49:04 PM Trade 4.25 100 12:49:00 PM Trade 4.25 900 12:49:00 PM Trade 4.25 100 12:48:58 PM Trade 4.25 900 12:48:58 PM Trade 4.25 100 12:48:02 PM Ask 4.28 100 most recent  next page 3:02:01 PM EST - Friday, December 3, 2004 - data is delayed 15 minutes

DJIA 10,585.50 0.40 Nasdaq 2,149.23 5.66 S&P 500 1,190.48 0.15 30 Yr Bond 4.94 0.11 10 Yr Bond 4.27 0.13 Select Time Frame Specify Time:        9:30a 9:45a 10:00a 10:15a 10:30a 10:45a 11:00a 11:15a 11:30a 11:45a 12:00a 12:15a 12:30a 12:45a 1:00p 1:15p 1:30p 1:45p 2:00p 2:15p 2:30p 2:45p 3:00p 3:15p 3:30p 3:45p 4:00p   Or Jump: fwd 1 min   back 1 min fwd 5 min   back 5 min fwd 10 min   back 10 min fwd 15 min   back 15 min fwd 30 min   back 30 min fwd 1 hr   back 1 hr fwd 2 hrs   back 2 hrs Select Action Type Trades, Bids, and Asks Trades only

Exchange market data provided by DTN Market Access. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither FreeRealTime.com nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the FreeRealTime.com site, a member has agreed to the FreeRealTime.com Member Agreement. Copyright © 1998-2

 

200000 zum Schluß des Tages. Was läuft da ab?

Ein gigantischer Umsatz bis September war der tagesumsatz dieser Aktie Im durchschnitt um die 10.000.

Hauptversammlung war am 17 Nov.




 

Du spekulierts auf Alzheimer-Medikamente?
Dann schau Dir doch auch mal Myriad (WKN 897518) an!

Der PRANA-chart gefällt mir sehr gut! Ich mag Aktien,
die aussehen, als könnten sie bald wachgeküßt werden!
Habe zuvor noch nie was gehört von dem Unternehmen.
Gehe vielleicht mal mit einer ersten Position rein?

Gruß
sertralin19  

Schau ich mir mal an.

Umsatz heute enttäuschend, warum gab es Freitag so dicke Umsätze?

gruß
gs  

(Printer friendly version) Prana Biotechnology Raises US$3.7 Million Through Exercise of 9.5 Million Options MELBOURNE, Australia, Dec 8, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN; ASX: PBT), today announced that 9.5 millionunlisted options expiring on December 1, 2004 were exercised prior to the expirydate. The options were originally largely owned by certain insiders anddirectors of the company then transferred to new owners, who in turn exercisedthem at a price of A$0.50 per share."We are pleased to receive this vote of confidence in Prana Biotechnology," saidJon Alsenas, CEO. "The US$3.73 million (A$4.75 million) raised will be used asworking capital for general corporate purposes. This includes conducting thepotentially pivotal PLACQUE study of PBT-1 in Alzheimer's disease that is due tostart in the first half of 2005."Prana Biotechnology had 117,384,155 ordinary shares outstanding as of December2, 2004, and this exercise of options increases the total issued shares to126,890,821.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site at http://www.pranabio.com.

 

523902 Stück, im Vergleich zum 31.12. das 20 fache. 

Prana receives Clinical Trials Authorisation in UK

Sydney, Jan 04, 2005 (RWE via COMTEX) -- (RWE Australian Business News) PranaBiotechnology Ltd has received a Clinical Trials Authorisation from theMedicines and Healthcare Products Regulatory Agency of the UK to initiate the"potentially pivotal" PLACQUE (Progression Limitation in Alzheimer's:ClioQUinol's Efficacy) Phase II/III clinical trial.The PLACQUE trial will be conducted over 52 weeks and will enrol 435 patients inthe UK, Australia and South Africa.The purpose of the study is to assess the efficacy of two dose levels of PBT-1(clioquinol) when added to the current therapy of patients with moderateAlzheimer's disease."Receiving CTA approval is a significant milestone for Prana," said CEO Dr JonAlsenas."When 2004 began, the future of PBT-1 was uncertain due in large part to patentlitigation and other concerns."Now as we begin 2005, the patent litigation with PN Gerolymatos SA is behind usand we are on the cusp of transforming Prana from an early-stage developmentcompany to a late-stage development company with the initiation of thepotentially pivotal PLACQUE trial."The CTA approval allows us to clear the first regulatory hurdle to establishingPBT-1 as the first truly effective therapy for Alzheimer's sufferers."We are extremely hopeful that PBT-1 will be the first drug to target what isbelieved to be the root cause of Alzheimer's disease - the accumulation ofamyloid plaques in the neocortex of the brain."Clioquinol appears to be one of the lead candidates to have a significantimpact on both clinical symptoms and disease progression."Prana shares rose 6c to 60c this morning.RWE Australian Business NewsURL:              rweabn.com.auCopyright 2004 RWEABN

 

Prana Biotechnology Receives Clinical Trials Authorization in UK to Initiate PLACQUE Phase II/III Study

MELBOURNE, Australia, Jan 04, 2005 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced it has receiveda Clinical Trials Authorization (CTA) from the Medicines and Healthcare ProductsRegulatory Agency (MHRA) of the United Kingdom to initiate the potentiallypivotal PLACQUE (Progression Limitation in Alzheimer's: ClioQUinol's Efficacy)Phase II/III clinical trial.-- CTA approval enables company to move forward     -- Study enables Prana to progress to late stage development company     -- Prana meets milestone outlined at Analyst Day     -- PBT-1 may be first drug to modify the progression of Alzheimer's        disease    Study SpecificsThe PLACQUE trial will be conducted over 52-weeks and will enroll 435 patientsin the United Kingdom, Australia and the Republic of South Africa. The purposeof the study is to assess the efficacy of two dose levels of PBT-1 (clioquinol)when added to the current therapy of patients with moderate Alzheimer's disease.The trial will be randomized, double blind and placebo-controlled. The primaryendpoint of the study will be to demonstrate a reduction in the progression ofAlzheimer's as measured by the Alzheimer's Disease Assessment Scale-cognition(ADAS-cog).Significant Milestone"Receiving CTA approval is a significant milestone for Prana," said Jon Alsenas,CEO of Prana. "When 2004 began, the future of PBT-1 was uncertain due in largepart to patent litigation and other concerns. Now as we begin 2005, the patentlitigation with P.N. Gerolymatos, S.A. is behind us and we are on the cusp oftransforming Prana from an early stage development company to a late stagedevelopment company with the initiation of the potentially pivotal PLACQUEtrial. The CTA approval allows us to clear the first regulatory hurdle toestablishing PBT-1 as the first truly effective therapy for Alzheimer'ssufferers."We are extremely hopeful that PBT-1 will be the first drug to target what isbelieved to be the root cause of Alzheimer's disease -- the accumulation ofamyloid plaques in the neocortex of the brain," continued Dr. Alsenas."Clioquinol appears to be one of the lead candidates to have a significantimpact on both clinical symptoms and disease progression."Outlook for 2005Prana expects to have two promising Alzheimer's drugs in the clinic, with thePBT-1 Phase II/III PLACQUE study initiating in the second quarter and the PBT-2Phase I clinical trial also commencing in early 2005. Moreover, Prana continuesto focus upon developing a pipeline of drugs for the treatment of otherdisorders where inappropriate protein aggregation plays a key role, such as inParkinson's disease."The Metal Theory"The prize-winning science behind PBT-1 is based upon what is known as "the metaltheory" of Alzheimer's disease. The theory is based on the premise that keymetals, such as zinc and copper, are required for the inappropriate aggregationof amyloid beta to form the amyloid plaques. These plaques are then thought tocause the neurodegeneration associated with Alzheimer's disease. PBT-1 is thefirst of Prana's Metal-Protein Attenuating Compounds (MPACs) to be studied in apotentially pivotal trial. The metal-mediated aggregation of proteins is alsothought to be a key contributor to the development of a variety of otherdegenerative disorders.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site at http://www.pranabio.com.This press release may contain "forward-looking statements" within the meaningof the Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.Contacts:     Investor Relations               Media Relations     Kathy Price                      Ivette Almeida     T: 212-983-1702 ext. 212         T: 212-983-1702 ext. 209SOURCE Prana Biotechnology LimitedCONTACT:          Kathy Price, +1-212-983-1702, ext. 212, or Ivette Almeida, +1-212-983-1702, ext. 209                  both for Prana Biotechnology LimitedURL:              http://www.prnewswire.com                  http://www.pranabio.comwww.prnewswire.comCopyright (C) 2005 PR Newswire. All rights reserved.KEYWORD:          AustraliaINDUSTRY KEYWORD: BIO                  HEA                  MTC

Leider finde ich die Austr. Seite nicht mehr.Sie sollen von 0,06 auf 0,6 heute gestiegen sein.

Kann mir bitte jemand einen Link dazu geben Danke.

Bei ASX, kriege ich den Kurs nicht um die Bohne.

Kürzel ist PBT

 

gruß

gs

 

 

In Berlin plus 33 % heute!  

am 16. genau, so stark anstieg, und exakt, da habe ich mich wieder plaziert!!  

 

 

und 10 %Plus. Das gibt heute Grund zum Feiern.

gut dass ich dick drin bin.  

Sind zu 13,5  % beteiligt.

Dann die NRB Developments,ca. 3 %
sowie G. Templer, 0,03 %
und Crystal Triangle zu 0,09 %

George Mihaly, hat am 17. November 83.333 Aktien und 300.000 Optionen und zwar gekauft zu 0,48 Aus.$, je Aktie.
Werde nicht schlau aus dieser Info, dann nochmal bzw. danach hat er 166.000 Aktien
Date of change dann 17.12.04

Weitere Geschäfte könnte ihr dem Link entnehmen. Habe nciht alles ausgedruckt.  

Dezember, deshalb die dicken Umsätze. Und dann am 17.12. das Aktien Optionsprogramm.

 

http://www.asx.com.au/asx/research/...ity=&industryGroup=NO#chart

 

 

 

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN

Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain   Charts provided by Telescan
1 Dy  2 Dy  5 Dy  10 Dy  1 Mo  6 Mo  1 Yr  2 Yr  5 Yr  10 Yr  Max  

Analyst: Rodman & Renshaw Rating: Market Outperform     Kurs: n/A  KGV:      Kursziel: 12  Update: new coverage     WKN: 753907   Update Prana Biotechnology Ltd. (Spons. ADRs): Mar 27.01.2005 11:57:28 Die Analysten von Rodman & Renshaw bewerten in ihrer Analyse vom Mittwoch, 26. Januar 2005 die Aktie von Prana Biotechnology Ltd. (Spons. ADRs) neu mit dem Rating "Market Outperform". Das Kursziel für die Aktie liegt momentan bei 12 $. -red-

Anzeige: 100% Rabatt auf das Agio bei: Immobilienfonds - Schiffsfonds - LV-Sekundärmarktfonds - Medienfonds - Windfonds - Venture Capital

Weitere Analysen zu Prana Biotechnology Ltd. (Spons. ADRs):  27.01.05 11:57  Update Prana Biotechnology Ltd. (Spons. ADRs): Mar weiter...

 

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN

Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain   Charts provided by Telescan
Entferntaste fkunktioniert nicht. kann nichts ändern sorry  

 

PRANA BIOTECHNOLOGY LIMITED (PBT)

The Company's business is the development of therapeutic drugs for age-related diseases.

On this page you will find:

Delayed share priceCompany detailsCompany announcementsClosing pricesPrice history chartDividendsExchange Traded OptionsWarrants

Delayed share price

Prices are delayed by at least 20 minutes. Retrieving any price indicates your acceptance of the Conditions.

Code Last % Change Bid Offer Open High Low Vol PBT0.5801.75%0.5700.5900.5700.5900.570119,942<!-- tower ad -->Advertisement <!-- AdSpace -->< iframe marginWidth=0 marginHeight=0 src="http://campaigns.f2.com.au/html.ng/cat=companies&ptype=research&site=asx&adspace=160x600" frameBorder=0 width=160 scrolling=no height=600 BORDERCOLOR="#000000">          < /iframe><!-- AdSpace --><!-- end tower ad -->

PRANA BIOTECHNOLOGY LIMITED details

Please note: ASX relies on third parties to provide the information contained in the company details table, and therefore is unable to assume any responsibility for the accuracy or timeliness of the information.

Issuer CodePBTSecuritiesASX Code, Security Description ------------------------------ PBT, Ordinary Fully Paid Official Listing Date28 March, 2000GICS Industry GroupPharmaceuticals & BiotechnologyExempt Foreign?NoInternet Addresshttp://www.pranabio.com/Registered Office AddressSuite 2 , 1233 High Street , ARMADALE , VICTORIA, AUSTRALIA, 3143 Head Office Telephone(03) 9824 8166 Head Office Fax(03) 9824 8161 Share RegistryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED
YARRA FALLS , 452 JOHNSTON STREET , ABBOTSFORD , VICTORIA, AUSTRALIA, 3067 Share Registry Telephone1300 787 171 (BKR ONLY) Directors / Senior ManagementDr Jonas Alsenas (Executive Director, CEO)
Mr Phillip Hains (CFO)
Prof. Colin Masters (Executive Director)
Mr Geoffrey Kempler (Executive Chairman)
Dr George Mihaly (Non Exec. Director)
Mr Brian Meltzer (Non Exec. Director)
Dr Ross Murdoch (Chief Op. Officer)
Company SecretaryMr Richard RevelinsPrincipal ActivitiesThe Company's business is the development of therapeutic drugs for age-related diseases.

PRANA BIOTECHNOLOGY LIMITED announcements

How are company announcements published on www.asx.com.au?  quelle: http://www.asx.com.au/asx/research/...lActivity=&industryGroup=NO  

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN

Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain    

wen ich mir den Tageschart von heute ansehe, draucht man sich über die Nervösen nicht zu wundern, die heute als Gewinnmitnahmen kamen, zu billig verkauft haben.

PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN

Chart Options    1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax  BarDotLineMountain   Charts provided by Telescan

und just sind wir wieder auf gestrigem Kursniveau!

 

....  

< script language=JavaScript> function qm_openLookup_1256() {      var w = 450;   var h = 350;   var winl = (screen.width - w) / 2;   var wint = (screen.height - h) / 2;   var winprops = 'height='+h+',width='+w+',top='+wint+',left='+winl+',toolbar=0,location=0,directories=0,status=0,menubar=0,scrollbars=1,resizable=1';   win = window.open("http://app.quotemedia.com/quotetools/clientForward?targetURL=" + escape('http://app.quotemedia.com/quotetools/popups/symbolLookup.jsp') + "&forwardURL=http%3A%2F%2Fwww.otcbb.com%2Fhelp%2Fcms_includes%2Fquote_module.htm", "SymbolLookup", winprops);   if (parseInt(navigator.appVersion) >= 4) {      win.window.focus();   }   } function qm_check_1256() {  fObj = document.qm_navForm_1256;  if(fObj["symbol"].value=="") {              fObj["symbol"].value = 'PRAN';        }   return true; } function qm_forward_1256(newIndex, newAction) {     document.qm_navForm_1256.elements[3].selectedIndex = newIndex;     if (qm_check_1256()) {   document.qm_navForm_1256.submit();  } }< /script> <!-- top bar of buttons --> Markets Quote Depth/LII Charts News Filings Streamer <!-- end top bar --> <!-- get quote bar -->   Get Quote:  MarketsDetailed QuoteDepth/Level II Charts News FilingsStreamer Symbol Lookup powered by   quotemedia.com <!-- end get quote bar -->

<!-- section heading --> Market Depth For Prana Biotechnology Ltd Ads Delayed (11:11 AM EST) <!-- end heading --> <!-- first table --><!-- third table --><!-- third table --> Level II Quotebook <!-- first table --><!-- second table --><!-- second table --> Time MMID Size  Bid 11:07 TRAC 1  4.500 ↑ 10:48 RODM 10  4.490 ↑ 10:39 NITE 5  4.490   10:23 BTRD 2  4.480   10:15 SCHB 3  4.450   10:48 GSCO 1  4.420 ↑ 09:24 SKYC 1  4.300 ↓ 09:30 CRWN 1  4.300   08:06 MLCO 1  4.200   08:59 TDCM 1  4.120 ↑ 11:04 BRUT 1  3.950 ↓ 07:30 HDSN 1  3.900   07:30 JEFF 1  3.780   07:30 EKNS 5  3.500   07:30 HILL 1  3.300   07:30 SUSQ 1  2.550   07:30 AFCO 1  2.000   07:30 BAMM 1  2.000   09:30 GVRC 1  1.090   09:25 PUGS 1  0.010 ↑ 07:30 ADFN 0  0.000   07:30 NOCI 0  0.000   07:30 NQMO 0  0.000   10:11 SIZE 0  0.000               Ask Size    MMID Time   4.560 11    SCHB 10:15   4.610 1    TRAC 11:07   4.620 1    GSCO 10:48   4.740 1    TDCM 08:59   4.750 1    SKYC 09:24   4.850 1    MLCO 08:06 ↓ 4.920 10    GVRC 09:30 ↑ 4.950 1    NITE 10:39   5.000 1    HILL 07:30   5.000 1    JEFF 07:30   5.040 5    EKNS 07:30   5.340 1    SUSQ 07:30   5.500 1    HDSN 07:30 ↓ 6.210 8    CRWN 09:30   6.400 1    BAMM 07:30   6.800 1    RODM 10:48   10.000 1    AFCO 07:30 ↑ 2,000.000 1    PUGS 09:25   0.000 0    BRUT 11:04                       Time & Sales Price Size Time 4.540 1000 10:39:54 4.540 1000 10:39:54 4.480 100 10:23:32 4.500 100 10:23:15 4.560 240 10:15:03 4.550 100 10:15:02 4.480 900 10:11:14 4.500 100 10:11:13 4.560 600 10:11:04 4.570 100 10:03:58 4.560 2400 10:03:58 4.570 1500 10:03:27 4.570 500 10:03:27 4.630 500 09:34:47 4.630 3000 09:34:47 4.680 100 01/31 4.700 1000 01/31 4.700 440 01/31 4.700 1000 01/31 4.700 200 01/31 4.690 100 01/31 4.690 500 01/31 4.660 300 01/31 4.660 2700 01/31 4.650 100 01/31 4.650 200 01/31 4.620 400 01/31 4.660 600 01/31 4.660 100 01/31 4.660 500 01/31

<!-- footer  --><!-- end footer  --> Copyright © 2004 QuoteMedia. All rights reserved. Terms of Use.Data delayed 15-20 min. EPS & PE Ratio are based on rolling 12 month figures. Provided by QuoteMedia, Market Data by NAQ.

<!--   End of Quotemedia.com Multi-Channel QuoteModule Code   -->
Der SCHB Makler steht schon wieder mit einer riesigen Menge zu dem niedrigsten Kurs drin. Heute sind es 1000, damals waren es 5000, als es bergab ging, weil ich bei codi welche zum Verkauf gestellt habe.

Allerdings damals konnte man Orders nicht streichen, ohne GEb. zu haben. Also ließ ich sie drin, das wurde mir zum Verhängnis.

Ich habe es jedenfalls ausdrucken lassen und sende es an die Security, weil ich meine Sache auch noch überprüfen lasssen muß.

Solche Zufälle gibt es nicht.

 

 

Die Rechnung auf sinkenden Kurs des Makler SCB  ging erst mal auf, alllerdings wurden zu dem Kurs nur wenige Stücke umgesetzt, prompt stellte sich ob dieses Verkaufsdrucks, die Hälfte des Tagesumsatzes sind 11`K, ein paar Dummies vor den Makler. Und der Kurs gab leider nach bis auf 4,50.

Was für ein Zufall aber, das Angebot, zu 4, 56 vom makler ist weg. und im Ask gibt es momentannichts mehr zu verschenken.

So ists recht!

Market Depth For Prana Biotechnology Ltd Ads Delayed (12:06 PM EST) <!-- end heading --> <!-- first table --><!-- third table --><!-- third table --> Level II Quotebook <!-- first table --><!-- second table --><!-- second table --> Time MMID Size  Bid 12:06 RODM 1  4.500 ↑ 10:39 NITE 5  4.490   10:23 BTRD 2  4.480   11:50 SCHB 3  4.450   12:06 GSCO 1  4.350 ↓ 09:24 SKYC 1  4.300 ↓ 09:30 CRWN 1  4.300   08:06 MLCO 1  4.200   08:59 TDCM 1  4.120 ↑ 12:06 BRUT 2  3.950   07:30 HDSN 1  3.900   07:30 JEFF 1  3.780   07:30 EKNS 5  3.500   07:30 HILL 1  3.300   07:30 SUSQ 1  2.550   07:30 AFCO 1  2.000   07:30 BAMM 1  2.000   11:46 GVRC 1  1.090   09:25 PUGS 1  0.010 ↑ 07:30 ADFN 0  0.000   07:30 NOCI 0  0.000   07:30 NQMO 0  0.000   12:06 SIZE 0  0.000   12:06 TRAC 0  0.000 ↓             Ask Size    MMID Time   4.730 1    BRUT 12:06   4.730 1    TRAC 12:06   4.740 1    TDCM 08:59   4.740 1    GSCO 12:06   4.750 1    SKYC 09:24   4.850 1    MLCO 08:06 ↑ 4.920 10    GVRC 11:46 ↑ 4.950 1    NITE 10:39 ↑ 4.980 1    SCHB 11:50   5.000 1    HILL 07:30   5.000 1    JEFF 07:30   5.040 5    EKNS 07:30   5.340 1    SUSQ 07:30   5.500 1    HDSN 07:30 ↓ 6.210 8    CRWN 09:30   6.400 1    BAMM 07:30   6.800 1    RODM 12:06   10.000 1    AFCO 07:30 ↑ 2,000.000 1    PUGS 09:25 ↓ 0.000 0    SIZE 12:06                     Time & Sales Price Size Time 4.500 360 11:53:20 4.500 100 11:53:17 4.500 100 11:53:16 4.500 100 11:53:15 4.500 100 11:53:15 4.500 100 11:53:14 4.520 400 11:53:14 4.500 100 11:53:14 4.500 500 11:53:08 4.510 300 11:46:19 4.530 200 11:46:18 4.540 1000 10:39:54 4.540 1000 10:39:54 4.480 100 10:23:32 4.500 100 10:23:15 4.560 240 10:15:03 4.550 100 10:15:02 4.480 900 10:11:14 4.500 100 10:11:13 4.560 600 10:11:04 4.570 100 10:03:58 4.560 2400 10:03:58 4.570 1500 10:03:27 4.570 500 10:03:27 4.630 500 09:34:47 4.630 3000 09:34:47 4.680 100 01/31 4.700 1000 01/31 4.700 440 01/31 4.700 1000 01/31

<!-- footer  --><!-- end footer  --> Copyright © 2004 QuoteMedia. All rights reserved. Terms of Use.Data delayed 15-20 min. EPS & PE Ratio are based on rolling 12 month figures. Provided by QuoteMedia, Market Data by NAQ.

<!--   End of Quotemedia.com Multi-Channel QuoteModule Code   -->

 

 

 

PBT

0.570

3.64%

0.570

0.580

0.560

0.570

0.550

24,930

 

 

Das wäre in USDollar dann 4,42

zum gestirigen Rückgan auf 4, 10 bringt das heute sicher 10 % Plus.